Esperion Therapeutics Inc (ESPR) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.62 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.15. Analysts had a consensus of $-0.77. During the same quarter in the previous year, the company posted $-0.55 EPS.
Many Wall Street Analysts have commented on Esperion Therapeutics Inc. WallachBeth Downgraded Esperion Therapeutics Inc on Jul 5, 2016 to ” Hold”, Price Target of the shares are set at $35.Shares were Reiterated by Needham on Jun 30, 2016 to “Buy” and Lowered the Price Target to $ 25 from a previous price target of $77 .Shares were Downgraded by RBC Capital Mkts on Jun 29, 2016 to ” Sector Perform” and Lowered the Price Target to $ 15 from a previous price target of $30 .
Esperion Therapeutics Inc closed down -0.11 points or -1.00% at $10.87 with 2,34,632 shares getting traded on Tusday. Post opening the session at $11.05, the shares hit an intraday low of $10.57 and an intraday high of $11.18 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 7, 2016, Mark E Mcgovern (director) purchased 5,000 shares at $10.00 per share price. According to the SEC, on May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price. On Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price, according to the Form-4 filing with the securities and exchange commission.
Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.